Graphite Bio discloses supplemental proxy details to resolve merger-related shareholder lawsuits

LENZ Therapeutics, Inc.

Two federal lawsuits filed in CA and DE allege proxy omissions on LENZ financials, advisor conflicts; 12 additional demand letters received.
Company voluntarily adds disclosures including Transaction Committee member compensation ($0 extra) and liquidation value of $2.86/sh in Feb 2024.
Liquidation analysis per share in March 2027: $0.10 low case, $0.19 high case based on $5.6M-$11.1M net cash.
Leerink DCF analysis yielded implied exchange ratio range of 2.8075-3.2957, valuing LENZ equity at $460M-$540M.
Graphite denies allegations, states proxy complies with law; no executive officers expected to serve in combined company post-merger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.